Sermaglutide 910463-68-2 CAS NO.910463-68-2

Superiority

1. Best prices with satisfied quality;

2. It's clients' right to choose the package's Courier (EMS, DHL, FedEx, UPS);

3. It's clients' right to choose the packing way for his produccts from many recent effective packing ways;

4. Specials are possible when client's order is big enough, including the discount policy;

5. Our company promise to deliver clients' package to his hands safely, as we concern your loss very much.

6ample order are welcomed.
 

Basic Information, Physical and Chemical Properties, Security Data, Frequently Asked Questions List, Somalutide Price (Reagent Grade)
Basic information
Chinese alias
Si Meilu
Somalutide
Somalutide
Somarutai
Somalutide impurity
Somalutide reference substance
Somalutide (semaglutide)
Somalutide peptide raw material commissioned production
Consistency Evaluation of Somalutide Peptide Preparations
Somalutide/Smeaglutide/Smeaglutide
English alias
semaglutide
Semaglutide impurity
Sermaglutide USP/EP/BP
Sermaglutide CAS 910463 68 2
Somaroutin
semgalutide
Somaglutide
Somarlutide
Sermaglutide
Somalutamide
Category
Raw materials: pancreatic hormones and other blood glucose regulating drugs
Physical and Chemical Properties
Storage conditions -20 ° C storage
Solubility DMSO: 3mg/mL (0.73 mM)
Form Solid
Color White to Off white
InChIKeyDLSWIYLPEUIQAV-CCUURXOWSA-N
safety data
GHS hazard pictograms
GHS08
Warning Words Warning
Hazard Description H361
Preventive instructions P201-P202-P281-P308+P313-P405-P501
Frequently Asked Questions List
brief introduction
Somaglutide is a new generation of GLP-1 (glucagon like peptide-1) analog developed by Daminol and NovoNordisk. Somaglutide is a long-acting dosage form developed based on the basic structure of Lilalutide, which has a better effect on the treatment of type 2 diabetes. Novo Nordisk has completed six Phase IIIa studies on Somalutide injection and submitted a new drug registration application for Somalutide once a week injection to the US Food and Drug Administration (FDA) on December 5, 2016. It has also submitted a marketing authorization application (MAA) to the European Medicines Agency (EMA). On the other hand, the once daily oral formulation of semaglutide is currently in Phase III clinical practice.

role
Somaglutide is a long-acting dosage form developed based on the basic structure of liraglutide, which has better effect in the treatment of type 2 diabetes.
preparation
Preparation of Somalutide via Solid Liquid Synthesis Method. The solid-phase synthesis method was used to prepare straight chain peptides Aib8, Arg34GLP-1 (7-37), and fatty side chain acylating agents. The synthesized fatty chain acylating agent was used to modify the straight chain peptide Lys26 under alkaline conditions to obtain semaglutide. The biological activity of the self-made samples was determined by time-resolved fluorescence resonance energy transfer immunoassay.
GLP-1 receptor agonist class new drugs
Semeglutide is a novel GLP-1 analogue that is injected subcutaneously once a week. Somalutide is a long-acting GLP-1 analogue developed by Novo Nordisk for once/w subcutaneous injection. Compared with liraglutide, semaglutide has a longer fatty chain and increased hydrophobicity, but it is modified with short chain PEG, greatly enhancing its hydrophilicity. PEG modification not only tightly binds to albumin, masking the DPP-4 enzyme hydrolysis site, but also reduces renal excretion, prolongs the biological half-life, and achieves the effect of long circulation. Novo Nordisk's Somalutide outperforms DPP-4's Sitagliptin and GLP-1's pioneer long-acting exenatide (which should be designed to compete head to head with Lily's Trucity, bullying has long been on the market). In the experiment, high-dose Soma reduced A1C by 1.6% and lowered body weight by up to 6kg.
Somaglutide was tested in 813 patients with type 2 diabetes to investigate the efficacy and safety of 1.0 mg Somaglutide compared with 2.0 mg Exenatide injected once a week. The trial period was 56 weeks, and the patients took 1-2 anti diabetes drugs orally at the same time.
In December 2017, the FDA officially approved the once weekly GLP-1 hypoglycemic drug Soraglutide developed by Novo Nordisk, marketed as Ozempic. According to clinical trial data, Ozempic can lower HbA1c levels compared to placebo, Merck's Januvia, AstraZeneca's Bydureon, and Sanofi's Lantus. The drug also shows the ability to help patients lose weight.
As a leader in the field of diabetes, Novo Nordisk not only has a third of the world in the field of insulin, but also has developed the human glucagon like peptide-1 (GLP-1) analog Liraglutide (trade name: Victoza), which has occupied the dominant position in the GLP-1 market since its listing in 2009. In 2016, the global sales reached 3.2 billion dollars, which can be described as fruitful.
The Liraglutide compound has expired, and generic drug companies are eyeing it closely. To prevent potential problems, Novo Nordisk has already prepared the next generation of Liraglutide, which is Somalutide. Structurally, Semeglutide replaces Ala at position 8 on the GLP-1 (7-37) chain with Aib, Lys at position 34 with Arg, and Lys at position 26 with an octadecanoic acid fatty chain. Compared with Liraglutide, Semeglutide has longer fatty chains and increased hydrophobicity, but its hydrophilicity is greatly enhanced by short chain PEG modification. PEG modification not only tightly binds to albumin, masking the DPP-4 enzyme hydrolysis site, but also reduces renal excretion, prolongs the biological half-life, and achieves the effect of long circulation.
According to analysis, Ozempic is expected to become one of the best-selling drugs of 2017. Novo Nordisk predicts drug sales to reach $2.2 billion in 2022. At the same time, Novo Nordisk is actively developing oral dosage forms of Somaglutide to gradually consolidate its dominance in the field of diabetes.
biological activity
Semaglutide (Rybelsus, Ozempic, NN9535, OG217SC, NNC 0113-0217) is a long-acting glucagon like peptide 1 (GLP-1) analog, an activator of GLP-1 receptor, and has potential therapeutic effect on type 2 diabetes (T2DM).